Shimomori Yuta, Yokoyama Yoshihiro, Kurumi Hiroki, Akita Kotaro, Kazama Tomoe, Hayashi Yuki, Mizukami Kazuhiro, Nakase Hiroshi
Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo 060-8543, Hokkaido, Japan; Tel: +81-11-611-2111.
Department of Gastroenterology, Faculty of Medicine, Oita University,1-1 Idaigaoka, Hasama, Yufu 879-5593, Oita, Japan; Tel: +81-97-586-4411.
EXCLI J. 2025 Jun 6;24:638-658. doi: 10.17179/excli2025-8374. eCollection 2025.
Ulcerative colitis (UC) is a chronic or recurrent inflammatory disease of the large intestine. Although the causes of UC are insufficiently understood, a complex interaction of several factors, including genetic factors, environmental factors, and gut microbiota, influences the onset of UC. The pathophysiology of UC involves intestinal barrier dysfunction, abnormal immune responses, and dysregulation of cytokines. Cytokine-targeted therapies have been approved for the treatment of UC, with several targeted therapies being currently available. The induction response rates range from 47.8 % to 73 %, and we often experience difficult-to-treat cases. In this review, we outlined the abnormal immune response and cytokine regulation underlying the complex pathology of UC. Moreover, we summarized the mode of action and the effects at the cellular and genetic levels of targeted therapies. A deeper understanding of the pathophysiology of UC and the effects of treatment is essential for advancing personalized medicine, which remains a key, challenging goal in the future management of UC.
溃疡性结肠炎(UC)是一种大肠的慢性或复发性炎症性疾病。尽管UC的病因尚未完全明确,但包括遗传因素、环境因素和肠道微生物群在内的多种因素之间的复杂相互作用会影响UC的发病。UC的病理生理学涉及肠道屏障功能障碍、异常免疫反应和细胞因子失调。细胞因子靶向疗法已被批准用于治疗UC,目前有几种靶向疗法可供使用。诱导缓解率在47.8%至73%之间,我们经常遇到难治性病例。在这篇综述中,我们概述了UC复杂病理背后的异常免疫反应和细胞因子调节。此外,我们总结了靶向疗法在细胞和基因水平上的作用方式和效果。深入了解UC的病理生理学和治疗效果对于推进个性化医疗至关重要,这仍然是未来UC管理中的一个关键且具有挑战性的目标。